Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Asunaprevir; Rosuvastatin Calcium

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy subjects with no clinically significant deviations from normal in medical history, physical exam findings, 12 lead ECG measurements and clinical laboratory tests

• Females must be of non-childbearing potential

Exclusion Criteria:

• Women of childbearing potential

• Any significant acute or chronic medical condition

• Inability to tolerate oral medications

• Inability to be venipunctured and/or tolerate venous access

• Abnormal liver function tests

• Current or recent (within 3 months of dosing) gastrointestinal disease